ABSTRACT
This chapter reviews published results of phase 1 and 2 trials of selected promising disease modifying therapies for multiple sclerosis (MS) (Table 28.1). Treatments that target the cytokine environment are reviewed first, followed by treat ments that may stabilize the blood-brain barrier. Finally, treatments directed against inflammatory cells (either by targeting autoreactive T cells or the tri-molecular complex are reviewed). A list of on-going studies for which there are no published data in patients with MS is also provided (Table 28.2).
